Precigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million

Reuters03-26

<a href="https://laohu8.com/S/PGEN">Precigen</a> FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million

Precigen published a press release reporting full-year 2025 financial results and business updates.
Total revenue rose 146.7% to USD 9.7 million, including USD 4 million in product revenues, net, and USD 3.9 million in service revenues.
Net loss attributable to common shareholders was USD 429.6 million, while operating loss was USD 110.5 million.
R&D expense fell 22.1% to USD 41.3 million, driven by reduced ActoBio costs after operations were closed in 2024 and lower external services following pipeline prioritization.
SG&A expense more than doubled to USD 70.1 million due to PAPZIMEOS commercial readiness spending; PAPZIMEOS generated USD 3.4 million in Q4 net product revenue, and cash, cash equivalents and investments totaled USD 100.4 million with management expecting this to fund operations to cash flow break-even.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603251605PR_NEWS_USPR_____NY17974) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622049420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622049420","market":"us","top_or_hot":-1,"title":"Precigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> FY2025 loss per share widens to $1.37; SG&amp;A expenses climb 69.8% to $70 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Precigen published a press release reporting full-year 2025 financial results and business updates.\n        </li>\n<li>\n          Total revenue rose 146.7% to USD 9.7 million, including USD 4 million in product revenues, net, and USD 3.9 million in service revenues.\n        </li>\n<li>\n          Net loss attributable to common shareholders was USD 429.6 million, while operating loss was USD 110.5 million.\n        </li>\n<li>\n          R&amp;D expense fell 22.1% to USD 41.3 million, driven by reduced ActoBio costs after operations were closed in 2024 and lower external services following pipeline prioritization.\n        </li>\n<li>\n          SG&amp;A expense more than doubled to USD 70.1 million due to PAPZIMEOS commercial readiness spending; PAPZIMEOS generated USD 3.4 million in Q4 net product revenue, and cash, cash equivalents and investments totaled USD 100.4 million with management expecting this to fund operations to cash flow break-even.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603251605PR_NEWS_USPR_____NY17974) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> FY2025 loss per share widens to $1.37; SG&amp;A expenses climb 69.8% to $70 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Precigen published a press release reporting full-year 2025 financial results and business updates.\n        </li>\n<li>\n          Total revenue rose 146.7% to USD 9.7 million, including USD 4 million in product revenues, net, and USD 3.9 million in service revenues.\n        </li>\n<li>\n          Net loss attributable to common shareholders was USD 429.6 million, while operating loss was USD 110.5 million.\n        </li>\n<li>\n          R&amp;D expense fell 22.1% to USD 41.3 million, driven by reduced ActoBio costs after operations were closed in 2024 and lower external services following pipeline prioritization.\n        </li>\n<li>\n          SG&amp;A expense more than doubled to USD 70.1 million due to PAPZIMEOS commercial readiness spending; PAPZIMEOS generated USD 3.4 million in Q4 net product revenue, and cash, cash equivalents and investments totaled USD 100.4 million with management expecting this to fund operations to cash flow break-even.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603251605PR_NEWS_USPR_____NY17974) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4pGh8V:1","article_id":"2622049420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622049420","pubTimestamp":1774469249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Precigen published a press release reporting full-year 2025 financial results and business updates.Total revenue rose 146.7% to USD 9.7 million, including USD 4 million in product revenues, net, and USD 3.9 million in service revenues.Net loss attributable to common shareholders was USD 429.6 million, while operating loss was USD 110.5 million.R&D expense fell 22.1% to USD 41.3 million, driven by reduced ActoBio costs after operations were closed in 2024 and lower external services following pipeline prioritization.SG&A expense more than doubled to USD 70.1 million due to PAPZIMEOS commercial readiness spending; PAPZIMEOS generated USD 3.4 million in Q4 net product revenue, and cash, cash equivalents and investments totaled USD 100.4 million with management expecting this to fund operations to cash flow break-even.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen","BK4139":"生物科技"},"translate_title":"Precigen 2025财年每股亏损扩大至1.37美元；SG&A费用攀升69.8%至7000万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":0.9},"content_text":"Precigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million\n    \n\n\n          Precigen published a press release reporting full-year 2025 financial results and business updates.\n        \n\n          Total revenue rose 146.7% to USD 9.7 million, including USD 4 million in product revenues, net, and USD 3.9 million in service revenues.\n        \n\n          Net loss attributable to common shareholders was USD 429.6 million, while operating loss was USD 110.5 million.\n        \n\n          R&D expense fell 22.1% to USD 41.3 million, driven by reduced ActoBio costs after operations were closed in 2024 and lower external services following pipeline prioritization.\n        \n\n          SG&A expense more than doubled to USD 70.1 million due to PAPZIMEOS commercial readiness spending; PAPZIMEOS generated USD 3.4 million in Q4 net product revenue, and cash, cash equivalents and investments totaled USD 100.4 million with management expecting this to fund operations to cash flow break-even.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603251605PR_NEWS_USPR_____NY17974) on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622049420","isCrawlerRequest":true}